Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT05211167

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD. (from the registry)
Registry
  • NCT NCT05211167
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05211167. Randomized; no masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2023-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
Condition
Kidney Failure, Chronic
Condition
Hemodialysis
Intervention (Drug)
Human Erythropoiesis Injection (CHO cell)
Intervention (Drug)
Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
Lead sponsor
Shenyang Sunshine Pharmaceutical Co., LTD. (class: industry)

Record details

Record id
cardio:ct-nct05211167
Content hash
3a129d645237904d428104a3ac048954b7043a3ddbaf7f6d2b26bc6e81039fcc